ID   XG-3
AC   CVCL_4799
SY   XG3; XG 3; XG-3P; XG3P
DR   ArrayExpress; E-TABM-937
DR   cancercelllines; CVCL_4799
DR   Cosmic; 742960
DR   Cosmic; 2809770
DR   IARC_TP53; 28498
DR   Wikidata; Q54994710
RX   DOI=10.1007/0-306-46877-8_4;
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=1373872;
RX   PubMed=1753108;
RX   PubMed=8204890;
RX   PubMed=10936422;
RX   PubMed=21173094;
RX   PubMed=30545397;
WW   Info; Keats Lab; -; https://www.keatslab.org/myeloma-cell-lines
CC   Characteristics: Produces Ig lambda.
CC   Characteristics: IL6 dependent.
CC   HLA typing: A*02,32; B*35,44; C*04,05 (Direct_author_submission).
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Unspecified (PubMed=21173094).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=21173094).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Transcriptomics; Microarray.
CC   Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck, Catherine.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: B-cell; CL=CL_0000236.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_HX21 ! XG-3E
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 24
//
RX   DOI=10.1007/0-306-46877-8_4;
RA   Jernberg-Wiklund H., Nilsson K.;
RT   "Multiple myeloma cell lines.";
RL   (In book chapter) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York; USA (2000).
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
//
RX   PubMed=1373872;
RA   Mazars G.-R., Portier M., Zhang X.-G., Jourdan M., Bataille F.-R.,
RA   Theillet C., Klein B.;
RT   "Mutations of the p53 gene in human myeloma cell lines.";
RL   Oncogene 7:1015-1018(1992).
//
RX   PubMed=1753108; DOI=10.4049/jimmunol.147.12.4402;
RA   Jourdan M., Zhang X.-G., Portier M., Boiron J.-M., Bataille F.-R.,
RA   Klein B.;
RT   "IFN-alpha induces autocrine production of IL-6 in myeloma cell
RT   lines.";
RL   J. Immunol. 147:4402-4407(1991).
//
RX   PubMed=8204890; DOI=10.1182/blood.V83.12.3654.3654;
RA   Zhang X.-G., Gaillard J.-P., Robillard N., Lu Z.-Y., Gu Z.-J.,
RA   Jourdan M., Boiron J.-M., Bataille F.-R., Klein B.;
RT   "Reproducible obtaining of human myeloma cell lines as a model for
RT   tumor stem cell study in human multiple myeloma.";
RL   Blood 83:3654-3663(1994).
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//
RX   PubMed=21173094; DOI=10.3324/haematol.2010.033456; PMCID=PMC3069235;
RA   Moreaux J., Klein B., Bataille F.-R., Descamps G., Maiga S., Hose D.,
RA   Goldschmidt H., Jauch A., Reme T., Jourdan M., Amiot M.,
RA   Pellat-Deceunynck C.;
RT   "A high-risk signature for patients with multiple myeloma established
RT   from the molecular classification of human myeloma cell lines.";
RL   Haematologica 96:574-582(2011).
//
RX   PubMed=30545397; DOI=10.1186/s13045-018-0679-0; PMCID=PMC6293660;
RA   Tessoulin B., Moreau-Aubry A., Descamps G., Gomez-Bougie P., Maiga S.,
RA   Gaignard A., Chiron D., Menoret E., Le Gouill S., Moreau P., Amiot M.,
RA   Pellat-Deceunynck C.;
RT   "Whole-exon sequencing of human myeloma cell lines shows mutations
RT   related to myeloma patients at relapse with major hits in the DNA
RT   regulation and repair pathways.";
RL   J. Hematol. Oncol. 11:137.1-137.13(2018).
//